The global pneumococcal vaccines market is projected to have an average-paced CAGR of 4.1% during the forecast period. The current valuation of the market is USD 8.9 Billion in 2023. The market value of the pneumococcal vaccines market is anticipated to surpass a market valuation of USD 13.3 Billion by 2033.
A historical market valuation of USD 8.5 Billion has been recorded by the analysts of Future Market Insights for the concerned market during the base year.
Growth is supported by:
| Report Attribute | Details |
|---|---|
| Pneumococcal Vaccines Market Value (2023) | USD 8.9 Billion |
| Pneumococcal Vaccines Market Anticipated Value (2033) | USD 13.3 Billion |
| Pneumococcal Vaccines Projected Growth Rate (2023 to 2033) | 4.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Although the market is estimated to have favorable growth through the forecast period, it is identified that certain factors prevailing in the market are likely to curb the demand for pneumococcal vaccines in the forthcoming years.
It is witnessed that the manufacturing or production process of pneumococcal vaccines requires a longer timeline, which acts as a key restraining element in the market expansion.
Additionally, there is a very high cost associated with the development of pneumococcal vaccines. Therefore, it is expected that the aforementioned factors are likely to hinder the propulsion of industry through the forecast period.
The industry players are diversifying their product portfolios with the launch of protein-based vaccines. The introduction of protein-based vaccines is creating several growth opportunities in the market to further expand and upscale the prominence of pneumococcal vaccines.
Protein-based vaccines have inexpensive production procedures that further aid the market’s prominence. Additionally, these products have logistical and protocol advantages, along with the inclusion of stability at a broad range of temperatures.
These vaccines are identified to narrow the immunization gaps that prevail among the middle-class and abundant populace across developing economies. Therefore, it is estimated that the pneumococcal vaccines market is likely to accrue significant shares through the forecast period.
Principal Consultant
It is identified that the pneumococcal vaccines market is witnessing an unprecedented surge in the recent few years. There has been an approximate rise of USD 0.4 Billion from the base year to the current.
This growth in market valuation can be highly attributed to the rising number of young children under 2 to 5 years possessing a high risk of pneumococcal diseases.
The rising geriatric population has also made a significant contribution to the industry growth of pneumococcal vaccines. Severe complications and contagiousness of diseases in old adults have fostered the growth of the pneumococcal vaccines market during the period 2018 to 2022.
The market advanced at a moderate pace of 3.2% CAGR and accounted for a market value of USD 8.5 Billion in the base year. It is identified that the rise in the number of diabetes patients, smokers, heavy drinkers, and individuals having chronic health conditions, who are vulnerable to ailments and infections owing to their weak immune systems is estimated to further fuel demand through the foreseen years.
Additionally, a key factor making a significant contribution to the market growth is the introduction of the Pneumococcal Conjugate Vaccine (PCV) by government agencies across emerging countries in infant routine immunization. This factor is expected to further trail growth through the projection period.
| Historical CAGR (2018 to 2022) | 3.2% |
|---|---|
| Market Value in 2022 | USD 8.5 Billion |
| Forecast CAGR (2023 to 2033) | 4.1% |
|---|---|
| Market Value in 2023 | USD 8.9 Million |
Prevenar-13 - By Product Type
It is identified that the Prevenar-13 segment by product type category is likely to trail at a significant rate through the forecast period. In the base year, this segment was advancing forward at a CAGR of 3.2% and is likely to hold dominant shares in the pneumococcal vaccines market through 2033.
This segment is projected to account for a revenue share of USD 9,500 Millionin 2023. The growing prominence of Prevenar 13 can be attributed to the inclusion of thirteen pneumococcus and serotypes. The hospital sector is giving this vaccine to patients due to the presence of serotypes 6A and 19A.
The Centers for Disease Control and Prevention (CDC) has also made recommendations for Prevenar-13 for adults, who are above the age of 65 years. Therefore, this segment is likely to accrue significant shares of the market through 2033.
Public Authorities - By Distribution Channel
After an in-depth analysis of the market, it is witnessed that the public authorities segment by distribution channel category is likely to hold dominant shares in the pneumococcal vaccines market. In 2022, this segment trailed at a CAGR of 6.8% and is likely to move forward at a notable pace, registering a CAGR of 5% during the period 2023 to 2033.
Public health agencies and community clinics are accounting for the largest market share owing to the large number of vaccine purchases made by organizations such as GAVI, WHO, UNICEF, and others. These organizations make bulk purchases of pneumonia vaccines and distribute them across diver geographies for social causes.
The hospital segment is also estimated to have grown at a significant rate and is projected to surpass a market valuation of USD 12,400 Million by the end of 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Region | North America |
|---|---|
| Country | United States of America |
| CAGR (2023 to 2033) | 1.8% |
| Region | Europe |
|---|---|
| Country | United Kingdom |
| CAGR (2023 to 2033) | 2.5% |
| Region | Europe |
|---|---|
| Country | Germany |
| CAGR (2023 to 2033) | 2.9% |
| Region | Asia Pacific |
|---|---|
| Country | China |
| CAGR (2023 to 2033) | 9.0% |
| Region | Asia Pacific |
|---|---|
| Country | India |
| CAGR (2023 to 2033) | 9.2% |
| Country | United States of America |
|---|---|
| Statistics | The USA is estimated to hold the highest share of the pneumococcal vaccines market through the projection period. The pneumococcal vaccines industry in the USA is advancing at a CAGR of 1.8%. the market is estimated to surpass a valuation of USD 4.9 Billion by the end of 2033. Approximate Growth in Market Value: USD 825.6 Million Historical CAGR: 0.4% |
| Growth Propellants | A well-established healthcare infrastructure across the North American region serving a large number of patients is estimated to foster the growth of the pneumococcal market in the upcoming years. It is identified that the 5-7% mortality rate in the USA is due to pneumococcal diseases. The rapid growth in the geriatric population is also a key factor fueling the market expansion of pneumococcal vaccines. |
| Country | Germany |
|---|---|
| Statistics | Germany is likely to hold a significant share of the pneumococcal vaccines market in the European region. The pneumococcal vaccines industry in the UK is advancing at a CAGR of 2.9%. The market is estimated to surpass a valuation of USD 191.9 Million by the end of 2033. Approximate Growth in Market Value: USD 47.2 Million Historical CAGR: 2.1% |
| Growth Propellants | The high prevalence and invasion of pneumonia across the people of Europe which accounted for approximately 15.08% of 1,00,000 people is a key cause fueling the market size of pneumococcal vaccines in Germany. A growing number of research and development activities and clinical trials aided by government advances in the country is reshaping the industry landscape in 2023. |
| Country | China |
|---|---|
| Statistics | The pneumococcal vaccines market in China is estimated to move forward at a substantial rate, slating a CAGR of 9.0% through the forecast period. The market is estimated to surpass a valuation of USD 2.9 Billion by the end of 2033. Approximate Growth in Market Value: USD 1.7 Billion Historical CAGR: 35.3% |
| Growth Propellants | The medical healthcare sector across China is witnessing a rise in investment from government authorities. Medical institutes across China are heavily using pneumococcal vaccines for treating diseases like meningitis, blood-stream infection, and more. Therefore, it is estimated to emerge as one of the most significant and remunerative markets in the pneumococcal vaccine landscape. |
The new entrants in the pneumococcal vaccines market are leveraging advancements in technology to launch new products and gain a competitive advantage. These firms are continually investing in research and development activities to keep themselves in tandem with the changing consumer preferences and end-use industry demands.
Efforts are being made to strengthen their foothold in the market and aid the further progression of the pneumococcal vaccines market.
Affinivax - This firm is a clinical-stage biopharmaceutical organization, who are having a next-generation technology platform for vaccines known as the multiple antigen presentation systems. This firm is likely to penetrate the market and be in tandem with the demand from the hospital sector through the forecast period.
GPN Vaccine - This is an Australian start-up firm that is offering vaccines for pneumonia. The startup sterilizes its proprietary, engineered, and avirulent strain of S. pneumonia with gamma rays to produce Gamma-PNTM, a whole-cell vaccine. The vaccine induces broad-spectrum immunity against the antigens of the pneumococcus bacterium and is effective against different pathogenic pneumococcal strains.
The pneumococcal vaccines market is highly fragmented and the key manufacturers are deploying several organic and inorganic growth strategies to compete with the existing players in the market.
The biggies are heavily investing in research and development activities to leverage advancements to the attributes of pneumococcal vaccines. They are making attempts for treating the chronic diseases prevailing amongst the geriatric population and others in an effective manner.
Activirosomes is developing vaccines for viral infections. The company is leveraging active virosome technology for the generation of non-replicating derivates of measles and some other comprehensive viruses. The virosome-based vaccines are carrying only the viral genes that are necessary for eliciting an immune response.
Recent Developments
The growth outlook for the market is predicted to advance at a CAGR of 4.1% from 2023 to 2033.
The North American region is anticipated to lead the market during the forecast period.
The market valuation of the market stands at USD 8.9 Billion in 2023.
The market is likely to hold a valuation of USD 13.3 Billion by 2033.
The healthcare industry sector is the key driver in the market.
1. Executive Summary 2. Market Overview 3. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type 4.1. Synflorix 4.2. Prevenar-13 4.3. PCV 13 (Pipeline) 4.4. V114 (Merck) 4.5. PCV-20 (Pfizer) 4.6. PCV-10 (SII) 4.7. PPSV-23 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channels 5.1. Wholesaler (Pharmacy channel) 5.2. Specialized Companies 5.3. Public Authorities 5.4. Others 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sector 6.1. Public 6.2. Private 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Europe 7.3. Asia Pacific 7.4. Latin America 7.5. Rest of the World 8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12. Rest of the World Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Glaxosmithkline plc. 15.2. LG Chem Ltd. 15.3. Merck & Co., Inc. 15.4. Panacea Biotec Limited 15.5. Pfizer Inc. 15.6. Pnuvax Incorporated 15.7. Serum Institute of India Pvt. Ltd. 15.8. Shenzhen Kangtai Biological Products Co., Ltd. 15.9. SK Bioscience 15.10. Walvax Biotechnology Co., Ltd. 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Pneumococcal Vaccines Market
